跳转至内容
Merck
CN

SML0817

Pivmecillinam

≥98% (HPLC)

别名:

Amdinocillin pivoxil

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C21H33N3O5S
化学文摘社编号:
分子量:
439.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
251-276-6
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +215 to +245°, c = 1 in ethanol

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

CC1(C)[C@H](C(OCOC(C(C)(C)C)=O)=O)N2C([C@](/N=C/N3CCCCCC3)([H])[C@@]2([H])S1)=O

InChI

1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/b22-12+/t14-,15+,17-/m1/s1

InChI key

NPGNOVNWUSPMDP-UTEPHESZSA-N

Application

Pivmecillinam has been used to test its efficacy as a breast cancer stem cells (CSCs) targeting agent.

Biochem/physiol Actions

Pivmecillinam is a β-lactam antibiotic and a pivaloyl-containing pro-drug. It belongs to the class of amidinopenicillin. Pivmecillinam is an oral anti-microbial agent that can be considered for treating E. coli urinary tract infection (UTI).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2). Pivmecillinam has been shown to have synergistic effects with several antibiotics including novobiocin and rifampin in gram negative bacteria.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Asa Sullivan et al.
Antimicrobial agents and chemotherapy, 49(1), 170-175 (2004-12-24)
The knowledge of the effects of antimicrobial agents on the normal vaginal microflora is limited. The objective of the present study was to study the ecological impact of pivmecillinam on the normal vaginal microflora. In 20 healthy women, the estimated
C-M Lokrantz et al.
Acta neurologica Scandinavica, 109(4), 297-301 (2004-03-16)
We describe the clinical and neurophysiological findings in a case of hyperammonemic encephalopathy. A 72-year-old woman taking valproate (VPA), as monotherapy for her partial epilepsy developed urinary tract infection. She was treated with pivmecillinam 600 mg daily. The following days
Sven A Ferry et al.
Scandinavian journal of primary health care, 25(1), 49-57 (2007-03-14)
To analyse associations between symptoms and bacteriuria in uncomplicated lower urinary tract infection in women (LUTIW) and to evaluate outcome of therapy with three different regimens of pivmecillinam or placebo. Prospective, multicentre, randomized, double-blind, and placebo-controlled therapy study. Symptoms registered



全球贸易项目编号

货号GTIN
SML0817-10MG04061837107207
SML0817-50MG04061832634838